RaymondDMengMD

PubMed

• 16 citations
  A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with...
  Geoffrey I. Shapiro, Patricia LoRusso, Daniel C. Cho, Luna Musib, Yibing Yan, Matthew Wongchenko, Ilsung Chang, Premal Patel, Iris T. Chan, Sandra M. Sanabria-Bohórque...> ;Investigational New Drugs. 2021 Feb 1
• 116 citations
  A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
  Cristina Saura, Desamparados Roda, Susana Roselló, Mafalda Oliveira, Teresa Macarulla, Jose Alejandro Perez-Fidalgo, Rafael Morales-Barrera, Juan Manuel Sanchís-García...> ;Cancer Discovery. 2017 Jan 1
• 70 citations
  A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients
  Andrew S. Epstein, Angelo E. Volandes, Ling Y. Chen, Kristen Gary, Yuelin Li, Patricia Agre, Tomer T. Levin, Diane Lauren Reidy, Raymond D. Meng, Neil H. Segal, Kennet...> ;Journal of Palliative Medicine. 2013 May 31
• 220 citations
  γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity
  Raymond D. Meng, Christopher C. Shelton, Yue Ming Li, Li-Xuan Qin, Daniel A. Notterman, Philip B. Paty, Gary K. Schwartz> ;Cancer Research. 2009 Jan 15
• 5 citations
  Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo
  Terence W. McGarvey, Raymond D. Meng, Omari Johnson, Wafik S. El-Deiry, S. Bruce Malkowicz> ;Urologic Oncology. 2001 Jul 1
• 109 citations
  p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ
  Raymond D. Meng, Wafik S. El-Deiry> ;Experimental Cell Research. 2001 Jan 15
• 93 citations
  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
  Raymond D. Meng, E. Robert McDonald, M. Saeed Sheikh, Albert J. Fornace, Wafik S. El-Deiry> ;Molecular Therapy. 2000 Feb 1
• 6 citations
  Comparative Gene Expression Profiling in Response to p53 in a Human Lung Cancer Cell Line
  Suisui Song, Timothy K. MacLachlan, Raymond D. Meng, Wafik S. El-Deiry> ;Biochemical and Biophysical Research Communications. 1999 Nov 2
• 2 citations
  "p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999.
  Timothy K. MacLachlan, Raymond D. Meng, Wafik S. El-Deiry> ;Journal of Cellular Physiology. 1999 Nov 1
• 28 citations
  Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
  Raymond D. Meng, Helen A. Shih, Nita S. Prabhu, Donna L. George, Wafik S. El-Deiry> ;Clinical Cancer Research. 1998 Jan 1
• 4 citations
  Tumor suppressor gene therapy for cancer: from the bench to the clinic
  Raymond D. Meng, Wafik S. El-Deiry> ;Drug Resistance Updates. 1998 Jan 1
• Join now to see all